↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"

A　B　C　D　E　F　G　H　 I 　J　K　L　M　N　O　P　Q　R　S　T　U　V　W　X　Y　Z　other

85 / 12,170 descriptions found* Show info (disease name, etc.) on mouse-over.
 No.   薬物名（臨床試験情報から抽出）   DrugBank   KEGG DRUG *   KEGG GENES *   KEGG PATHWAY   指定難病告示番号 * 
 1   0.5 mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 2   1 mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 3   1mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 4   2mg budesonide effervescent tablet for orodispersible use   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 5   5 mg montelukast   Montelukast   D00529, D08229   1件: CYSLTR1   2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction   1件:
98 
 6   Ak002   -   -   -   -   1件:
98 
 7   Allergy immunotherapy (allergy shots)   -   -   -   -   1件:
98 
 8   Apt-1011   -   -   -   -   1件:
98 
 9   Barium   Barium   -   -   -   1件:
98 
 10   Beclomethasone dipropionate   Beclomethasone dipropionate   D00689, D07495   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   2件:
97,
98 
 11   Bethanechol   Bethanechol   D01000   5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway   1件:
98 
 12   Budesonide   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   9件:
66,
93,
94,
95,
96,
97,
98,
228,
299 
 13   Budesonide 0.5mg orodispersible tablet twice daily   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 14   Budesonide 1mg orodispersible tablet twice daily   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 15   Budesonide [0.4mg/ml] viscous suspension   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 16   Budesonide oral suspension   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 17   Budesonide oral suspension [0.2 mg/ml]   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 18   Budesonide plus prevacid   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 19   Buet 0.5 mg   -   -   -   -   1件:
98 
 20   Buet 1mg   -   -   -   -   1件:
98 
 21   Buet 2mg   -   -   -   -   1件:
98 
 22   Buu 0.4mg/ml   -   -   -   -   1件:
98 
 23   Cromolyn   Cromoglicic acid   D00526, D07753   -   -   2件:
85,
98 
 24   Dexlansoprazole   Dexlansoprazole   D08903   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   1件:
98 
 25   Dupilumab   Dupilumab   D10354   1件: IL4R   8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation   1件:
98 
 26   Dupilumab (blinded)   Dupilumab   D10354   1件: IL4R   8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation   1件:
98 
 27   Dupilumab (open-label)   Dupilumab   D10354   1件: IL4R   8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation   1件:
98 
 28   Esomeprazole   Esomeprazole   D01984, D04056, D07917, D09339   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   6件:
6,
46,
86,
98,
298,
299 
 29   Eur-1100   -   -   -   -   1件:
98 
 30   Florence 30 µg/ml   -   -   -   -   1件:
98 
 31   Florence 60 µg/ml   -   -   -   -   1件:
98 
 32   Florence 90 µg/ml   -   -   -   -   1件:
98 
 33   Flovent   Fluticasone propionate   D01708   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 34   Flovent (fluticasone propionate)   Fluticasone propionate   D01708   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 35   Fluticasone   Fluticasone   D07981   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   4件:
98,
228,
299,
306 
 36   Fluticasone mdi   Fluticasone   D07981   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 37   Fluticasone propionate   Fluticasone propionate   D01708   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   3件:
98,
228,
306 
 38   Honey   Honey   D06776   -   -   2件:
57,
98 
 39   Infliximab   Infliximab   D02598   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   22件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
95,
96,
97,
98,
162,
164,
269,
271 
 40   Inhaled/swallowed budesonide   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 41   Intubated with propofol (ip)   Propofol   D00549   16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   1件:
98 
 42   Intubated with sevoflurane (is)   Sevoflurane   D00547   -   -   1件:
98 
 43   Lansoprazole   Lansoprazole   D00355   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   6件:
63,
71,
98,
166,
222,
299 
 44   Losartan   Losartan   D00357, D08146   1件: AGTR1   14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   18件:
13,
17,
19,
46,
58,
66,
67,
85,
96,
97,
98,
113,
164,
167,
179,
215,
222,
299 
 45   Losartan potassium   Potassium   D08403   -   -   4件:
98,
167,
179,
215 
 46   Mepolizumab   Mepolizumab   D04923   1件: IL5   13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   4件:
44,
45,
98,
162 
 47   Mepolizumab 100 mg   Mepolizumab   D04923   1件: IL5   13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   1件:
98 
 48   Mepolizumab 300 mg   Mepolizumab   D04923   1件: IL5   13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   1件:
98 
 49   Monitor   Methamidophos   -   -   -   12件:
2,
11,
13,
19,
46,
49,
58,
70,
85,
98,
298,
300 
 50   Montelukast   Montelukast   D00529, D08229   1件: CYSLTR1   2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction   5件:
13,
46,
85,
98,
228 
 51   Montelukast/ singulair   Montelukast   D00529, D08229   1件: CYSLTR1   2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction   1件:
98 
 52   Nasonex   Mometasone furoate   D00690   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 53   Nitric oxide   Nitric oxide   D00074   -   -   7件:
46,
85,
86,
98,
251,
294,
299 
 54   Oc000459   -   -   -   -   1件:
98 
 55   Omalizumab   Omalizumab   D05251   1件: FCER1A   4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway   6件:
53,
65,
98,
162,
226,
299 
 56   Omeprazole   Omeprazole   D00455, D01207, D05259, D05261   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   15件:
6,
8,
13,
46,
51,
85,
96,
97,
98,
225,
271,
282,
294,
298,
299 
 57   Omeprazole 20mg bid   Omeprazole   D00455, D01207, D05259, D05261   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   1件:
98 
 58   Oral budesonide   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 59   Oral budesonide suspension (mb-9)   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 60   Oral budesonide suspension (obs)   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 61   Oral cromolyn sodium   Cromoglicic acid   D00526, D07753   -   -   1件:
98 
 62   Oral viscous budesonide   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 63   Oral viscous budesonide (ovb)   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 64   Potassium   Potassium   D08403   -   -   9件:
46,
66,
67,
98,
115,
167,
179,
215,
235 
 65   Propofol   Propofol   D00549   16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   8件:
6,
21,
22,
34,
46,
84,
98,
296 
 66   Qax576   -   -   -   -   4件:
51,
85,
96,
98 
 67   Reslizumab   Reslizumab   D08985   1件: IL5   13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   3件:
44,
45,
98 
 68   Rpc4046   -   -   -   -   1件:
98 
 69   Sb-240563   -   -   -   -   3件:
44,
45,
98 
 70   Sch55700   -   -   -   -   1件:
98 
 71   Sevoflurane   Sevoflurane   D00547   -   -   5件:
6,
21,
22,
98,
296 
 72   Sirolimus   Sirolimus   D00753   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   30件:
13,
17,
34,
35,
36,
46,
51,
60,
62,
63,
65,
66,
67,
85,
89,
96,
98,
137,
157,
158,
192,
222,
277,
278,
279,
280,
281,
283,
285,
331 
 73   Steroid and proton pump inhibitor therapy   -   -   -   -   1件:
98 
 74   Sucralfate   Sucralfate   D00446   -   -   1件:
98 
 75   Swallowed fluticasone   Fluticasone   D07981   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 76   Technetium tc 99m   Technetium tc-99m   -   -   -   1件:
98 
 77   Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms   Lansoprazole   D00355   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   1件:
98 
 78   Viaskin milk 500 mcg   -   -   -   -   1件:
98 
 79   Viscous/swallowed budesonide   Budesonide   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98 
 80   Vitamin d   Vitamin d   -   -   -   18件:
13,
19,
41,
46,
49,
50,
68,
93,
95,
96,
98,
179,
222,
228,
235,
274,
298,
299 
 81   Vonoprazan   Vonoprazan   -   -   -   2件:
63,
98 
 82   Wheat   Wheat   D06902   -   -   2件:
98,
266 
 83   Xanthan gum   Xanthan gum   D06333   -   -   1件:
98 
 84   Xylose   Xylose   D06346   -   -   1件:
98 
 85   Zofran - no intubation   -   -   -   -   1件:
98 

先頭へ